Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

Ítems similars

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
  per: Maddalena Mazzucchelli, et al.
  Publicat: (2018-01-01)
• Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
  per: Jorge J Castillo, et al.
  Publicat: (2023-02-01)
• A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia
  per: Rayan Kaedbey, et al.
  Publicat: (2022-09-01)
• Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors
  per: Jingjing Zhu, et al.
  Publicat: (2023-04-01)
• A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia
  per: Yi Xia, et al.
  Publicat: (2026-12-01)